What question did this study set out to answer?

Examine the therapeutic effects of combining PARP and RAS inhibitors on tumor growth in pancreatic cancer.

April 5, 2026Cancer Research

Dual Targeting of PARP and RAS in Pancreatic Cancer Therapy

View Full Paper

Ask AI

Bookmark

Authors

CSChani StosselSheba Medical Center GAGali AltmanSheba Medical Center DADikla Atias

Discussion

Member takes

Implication

Preclinical models demonstrate enhanced tumor suppression through combined PARP and RAS inhibition, indicating potential for broader PDAC treatment strategies.

Key Points

Examine the therapeutic effects of combining PARP and RAS inhibitors on tumor growth in pancreatic cancer.
Established patient-derived xenografts and organoid models for analysis.
Utilized olaparib and dual RAS inhibitors in both in vitro and in vivo studies.
Performed whole genome sequencing and RNA sequencing to analyze effects across different models.
Combination treatment significantly reduced tumor growth rates in preclinical models (p<0.05).
Notable additive effects observed with combined PARP and RAS inhibition in organoids and patient-derived cells.
Enhanced responses identified in BRCAmut and BRCA-WT models.

Cite This Study

Stossel et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd4ea79560c99a0a340f https://doi.org/10.1158/1538-7445.am2026-6488

View Full Paper

Ask AI

Bookmark

Implication

Preclinical models demonstrate enhanced tumor suppression through combined PARP and RAS inhibition, indicating potential for broader PDAC treatment strategies.

Dual Targeting of PARP and RAS in Pancreatic Cancer Therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Dual Targeting of PARP and RAS in Pancreatic Cancer Therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider